SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
May 20, 2020 |
|
| Movement in valuation and qualifying accounts | |||
| Allowance for cash discounts | $ 900 | $ 1,300 | |
| Increase (decrease) in valuation allowance | (2,100) | 13,100 | |
| Zyla Life Sciences | |||
| Movement in valuation and qualifying accounts | |||
| Provisions for liabilities assumed | $ 33,300 | ||
| Sales & return allowances, discounts, chargebacks and rebates: | |||
| Movement in valuation and qualifying accounts | |||
| Balance at Beginning of Year | 64,442 | 60,183 | |
| Additions / Charged as a Reduction to Revenue | 96,332 | 132,340 | |
| Deductions | (107,174) | (128,081) | |
| Balance at End of Year | 53,600 | 64,442 | |
| Deferred tax asset valuation allowance: | |||
| Movement in valuation and qualifying accounts | |||
| Balance at Beginning of Year | 103,906 | 90,820 | |
| Additions / Charged as a Reduction to Revenue | 0 | 29,833 | |
| Deductions | (2,131) | (16,747) | |
| Balance at End of Year | $ 101,775 | $ 103,906 | |